-
公开(公告)号：US20180127722A1
公开(公告)日：2018-05-10
申请号：US15416502
申请日：2017-01-26
Inventor： Shao-Chih Chiu , Wan-Sin Syu , Ming-Hsi Chuang , Po-Cheng Lin
IPC: C12N5/0775 , A61K35/28
CPC classification number: C12N5/0667 , A61K35/28 , C12N2500/30 , C12N2500/76
Abstract: A composition for treatment of tendonitis is provided. The composition comprises a pretreated adipose derived stem cell (ADSC), wherein the ADSC is pretreated with butylidenephthalide, and the concentration of butylidenephthalide is greater or equal to. The composition of the invention has abilities to repair damaged tendon fiber, enhance tissue regeneration, and decrease inflammation. The invention also provides a method for manufacturing a composition for treatment of tendonitis, comprising culturing an ADSC in a medium containing butylidenephthalide.
-
公开(公告)号：US20160303168A1
公开(公告)日：2016-10-20
申请号：US14552014
申请日：2014-11-24
Inventor： Shinn-Zong LIN , Horng-Jyh Harn , Ru-Huei Fu , Shih-Ping Liu , Po-Cheng Lin , Ming-Hsi Chuang
IPC: A61K35/28 , A61K31/365 , C12N5/0775
CPC classification number: A61K35/28 , A61K31/365 , A61K35/545 , C12N5/0667 , C12N2501/40 , C12N2501/999
Abstract: A method for enhancing the therapeutic effect of a stem cell is provided. The method comprises treating the stem cell with ligustilide, wherein the treatment is conducted in a culture medium of the stem cell. A method of stem cell treatment is also provided, comprising administering to a subject in need an effective amount of a stem cell or a combination of ligustilide and a stem cell, wherein the stem cell has been treated with ligustilide
Abstract translation: 提供了增强干细胞治疗效果的方法。 该方法包括用罗替司特治疗干细胞，其中处理在干细胞的培养基中进行。 还提供了一种干细胞治疗方法，其包括向有需要的受试者施用有效量的干细胞或罗替司肽与干细胞的组合，其中所述干细胞已用罗替司列
-
23.发明申请METHOD FOR ENHANCING THERAPEUTIC EFFECT OF STEM CELLS ON AUTOIMMUNE DISEASES, CARDIOVASCULAR DISEASES, AND/OR HEMATOLOGICAL DISEASES 有权干细胞治疗自身免疫性疾病，心血管疾病和/或血液病的治疗方法公开(公告)号：US20160075999A1
公开(公告)日：2016-03-17
申请号：US14821309
申请日：2015-08-07
Inventor： Shinn-Zong LIN , Horng-Jyh Harn , Ru-Huei Fu , Shih-Ping Liu , Po-Cheng Lin , Ming-Hsi Chuang
IPC: C12N5/0775 , A61K35/28 , A61K35/545
CPC classification number: A61K35/28 , A61K31/365 , A61K35/545 , C12N5/0667 , C12N2501/40 , C12N2501/999
Abstract: A method for enhancing the therapeutic effect of a stem cell on autoimmune diseases, cardiovascular diseases, and/or hematological diseases is provided. The method comprises treating the stem cell with ligustilide, wherein the treatment is conducted in a culture medium of the stem cell. A method of stem cell treatment is also provided, comprising administering to a subject suffering from autoimmune diseases, cardiovascular diseases, and/or hematological diseases an effective amount of a stem cell or a combination of ligustilide and a stem cell, wherein the stem cell has been treated with ligustilide.
Abstract translation: 提供了一种用于增强干细胞对自身免疫性疾病，心血管疾病和/或血液疾病的治疗效果的方法。 该方法包括用罗替司特治疗干细胞，其中处理在干细胞的培养基中进行。 还提供了一种干细胞治疗方法，其包括对患有自身免疫性疾病，心血管疾病和/或血液疾病的受试者施用有效量的干细胞或光灭活素与干细胞的组合，其中所述干细胞具有 用ligustilide治疗。
-
公开(公告)号：US20250144150A1
公开(公告)日：2025-05-08
申请号：US19012977
申请日：2025-01-08
Inventor： Po-Cheng Lin , Pi-Chun Huang , Chia-Hsin Lee , Ming-Hsi Chuang , Chun-Hung Chen , Chao-Liang Chang , Kai-Ling Zhang , Yi-Chun Lin , Yu-Chen Tsai , Peggy Leh Jiunn Wong , Ruei-Yue Liang
IPC: A61K35/28 , A61K9/00 , A61K38/18 , A61K38/19 , A61K38/20 , A61K45/06 , A61P25/28 , C12N5/00 , C12N5/0775
Abstract: The present invention provides a preparation method of pharmaceutical composition for treating chronic stroke, involving injection via brain into the cranium of a patient having chronic stroke for six months or more; the pharmaceutical composition is a suspension at least comprising adipose-derived stem cells treated by cell expansion, an active synergistic component and a growth factor, wherein the expression level of CD34 and CD45 of the adipose-derived stem cells treated by cell expansion is 10% or less, and the expression level of CD90 and CD105 is 90% or more; the active synergistic component is an extracellular vesicle; the growth factor is at least one selected from the group consisting of HGF, G-CSF, Fractalkine, IP-10, EGF, IL-1α, IL-1β, IL-4, IL-5, IL-13, IFNγ, TGFα and sCD40L. The present invention overcomes the limitations of previous cell therapy and provides a cell-based preparation that is clinically safe and therapeutically effective for chronic cerebral stroke.
-
Patent Agency Ranking
公开(公告)号：US20240075071A1
公开(公告)日：2024-03-07
申请号：US17993823
申请日：2022-11-23
Inventor： Ruei-Yue Liang , Kai-Ling Zhang , Ming-Hsi Chuang , Po-Cheng Lin , Peggy Leh Jiunn Wong , Chia-Hsin Lee
IPC: A61K35/28 , C12N5/0775
CPC classification number: A61K35/28 , C12N5/0667 , C12N2500/32 , C12N2500/38 , C12N2500/60 , C12N2500/90 , C12N2501/115 , C12N2501/15
Abstract: Disclosed in the present invention is an optimized cell transplant. The optimized cell transplant is formed by performing gene induction and modification on a mesenchymal stem cell in the form of a small molecule and protein composition. The expression levels of CD200 gene, Galectin-9 gene and VISTA gene can be increased synchronously after cell culture. Vector virus infection and plasmid transfection are not required in the cell preparation process, so that high biological safety and great clinical application value of cells are achieved. The optimized cell transplant is suitable for the technical field of mesenchymal stem cells applied to cell transplantation therapy, and the therapeutic effect of the optimized cell transplant is more excellent than that of the non-modified mesenchymal stem cell
-
公开(公告)号：US20230407262A1
公开(公告)日：2023-12-21
申请号：US18055409
申请日：2022-11-14
Inventor： Wei Wu Li , Tzyy-Wen Chiou , Horng-Jyh Harn , Shinn-Zong Lin , Ming-Hsi Chuang , Po-Cheng Lin , Chia-Hsin Lee , Mao-Hsuan Huang
IPC: C12N5/0775 , C12N5/079 , C07K14/435 , A61K38/17 , A61P25/00
CPC classification number: C12N5/0663 , C12N5/0618 , C07K14/435 , A61K38/17 , A61P25/00
Abstract: The present invention provides a medicine for treating a neurodegenerative disease, which employs LEFTY2 (Left-Right Determination Factor 2) generated by co-culturing mesenchymal stem cells of mammals with nerve cells having mutations in the APP (Amyloid precursor protein) gene, or a specific protein. The LEFTY2 has an effect of inhibiting Beta amyloid and a hyperphosphorylated neuronal microtubule-associated protein (Tau protein), without affecting the development of nerve cells and having the ability to promote the growth of the nerve cells; and the two types of proteins have a crucial impact on the neurodegenerative diseases.
-
公开(公告)号：US20210371812A1
公开(公告)日：2021-12-02
申请号：US17235910
申请日：2021-04-20
Inventor： Ruei-Yue Liang , Kai-Ling Zhang , Ming-Hsi Chuang , Po-Cheng Lin , Chun-Hung Chen , Pei-Syuan Chao
Abstract: The present invention relates to a cell differentiation medium composition, a high secretion insulin-producing cells and a preparation method thereof. The high secretion insulin-producing cells obtained by using the cell differentiation medium composition to induce stem cell differentiated under specific conditions can secrete a large amount of insulin in a short time, and when the high-secreting insulin-producing cells are transplanted into the human body, they are not easy to be swallowed by macrophages, which can improve the survival rate of the insulin-producing cells and prolong the time of insulin secretion thereby.
-
公开(公告)号：US09815959B2
公开(公告)日：2017-11-14
申请号：US14632730
申请日：2015-02-26
Inventor： Jui-Yang Lai , Kao-Yuan Chang , Zih-Han Hong , Po-Cheng Lin , Ming-Hsi Chuang
IPC: C08J9/36 , A61K35/35 , A61L27/22 , A61L27/56 , A61L27/58 , A61K35/28 , A61K9/50 , A61L27/16 , A61L27/18 , A61L27/50
CPC classification number: C08J9/36 , A61K9/5031 , A61K35/28 , A61K35/35 , A61L27/16 , A61L27/18 , A61L27/22 , A61L27/50 , A61L27/56 , A61L27/58 , A61L2300/222 , A61L2300/236 , A61L2300/25 , A61L2300/252 , A61L2300/64 , A61L2430/28 , C08J2207/10 , C08J2367/04 , C08J2405/08 , C08L67/04 , C08L29/04
Abstract: A method for manufacturing a hollow particle is provided. The method comprises the steps of (a) providing a hollow particulate; (b) soaking the hollow particulate in an amine solution to form amine groups on the surface of the hollow particulate; (c) adding a polypeptide, and the polypeptide is linked to the amine groups on the surface of the hollow particulate; and (d) adding a target molecule, and the target molecule is bound to the amine group which are still not bound.
-
公开(公告)号：US09533012B2
公开(公告)日：2017-01-03
申请号：US14552014
申请日：2014-11-24
Inventor： Shinn-Zong Lin , Horng-Jyh Harn , Ru-Huei Fu , Shih-Ping Liu , Po-Cheng Lin , Ming-Hsi Chuang
IPC: C12N5/00 , C12N5/02 , A61K35/28 , C12N5/0775 , A61K35/545 , A61K31/365
CPC classification number: A61K35/28 , A61K31/365 , A61K35/545 , C12N5/0667 , C12N2501/40 , C12N2501/999
Abstract: A method for enhancing the therapeutic effect of a stem cell is provided. The method comprises treating the stem cell with ligustilide, wherein the treatment is conducted in a culture medium of the stem cell. A method of stem cell treatment is also provided, comprising administering to a subject in need an effective amount of a stem cell or a combination of ligustilide and a stem cell, wherein the stem cell has been treated with ligustilide.
Abstract translation: 提供了增强干细胞治疗效果的方法。 该方法包括用罗替司特治疗干细胞，其中处理在干细胞的培养基中进行。 还提供了一种干细胞治疗方法，其包括对有需要的受试者施用有效量的干细胞或罗替沙特与干细胞的组合，其中所述干细胞已用罗替司列治疗。
-
-
-
-
-
-
-
-
Search Results
29
records
(took 0.02 seconds)
